A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
Completed · Phase 1
Conditions studied: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
In brief
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
Key facts
- Study ID
- NCT03835884
- Run by
- Aerie Pharmaceuticals
- People needed
- 18
- Starts
- 2019-06-24
- Expected to finish
- 2022-05-12
- Last updated by the study team
- 2023-02-09
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Retinal Research Institute, LLC — Gilbert, Arizona, United States
- Retina-Vitreous Associates Medical Group — Beverly Hills, California, United States
- Bay Area Retina Associates — Walnut Creek, California, United States
- Sterling Vision, PC dba Oregon Retina — Eugene, Oregon, United States
- Valley Retina Institute, P.A. — Harlingen, Texas, United States
- Medical Center Ophthamology Associates — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.